Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ATG-101 by Antengene for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
ATG-101 is under clinical development by Antengene and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
ATG-101 by Antengene for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
ATG-101 is under clinical development by Antengene and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC)....
ATG-101 by Antengene for Glioblastoma Multiforme (GBM): Likelihood of Approval
ATG-101 is under clinical development by Antengene and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...
ATG-101 by Antengene for Gastric Cancer: Likelihood of Approval
ATG-101 is under clinical development by Antengene and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
ATG-101 by Antengene for Cervical Cancer: Likelihood of Approval
ATG-101 is under clinical development by Antengene and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
ATG-101 by Antengene for Colorectal Cancer: Likelihood of Approval
ATG-101 is under clinical development by Antengene and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
ATG-037 by Antengene for Hematological Tumor: Likelihood of Approval
ATG-037 is under clinical development by Antengene and currently in Phase II for Hematological Tumor. According to GlobalData, Phase II...
ATG-031 by Antengene for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval
ATG-031 is under clinical development by Antengene and currently in Phase I for Transitional Cell Cancer (Urothelial Cell Cancer). According...
ATG-031 by Antengene for Liver Cancer: Likelihood of Approval
ATG-031 is under clinical development by Antengene and currently in Phase I for Liver Cancer. According to GlobalData, Phase I...
ATG-031 by Antengene for Ovarian Cancer: Likelihood of Approval
ATG-031 is under clinical development by Antengene and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I...
ATG-031 by Antengene for Lung Cancer: Likelihood of Approval
ATG-031 is under clinical development by Antengene and currently in Phase I for Lung Cancer. According to GlobalData, Phase I...
ATG-031 by Antengene for Breast Cancer: Likelihood of Approval
ATG-031 is under clinical development by Antengene and currently in Phase I for Breast Cancer. According to GlobalData, Phase I...